pharmaphorum December 7, 2021
Roche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and “industrialised” drug discovery to find new neuroscience and cancer drugs.
The Swiss drugmaker is paying $150 million upfront to kick off the strategic-level partnership, which could cover as many as 40 programmes and could be worth “several billion dollars”, according to Salt Lake City-based Recursion.
At $300 million per target, if Roche does take 40 programmes forward and they are all successful – which of course isn’t a likely scenario – the alliance could be worth a whopping $12 billion.
The deal – which is weighted heavily towards neuroscience with just one cancer programme covered – is the second between Recursion and a...
Today's Sponsors
Today's Sponsor